Congenital Disorder of Glycosylation Type iio

Congenital disorder of glycosylation type IIo is a very rare genetic condition where the body has trouble doing glycosylation (adding sugar “chains” to proteins). Those sugar chains help proteins fold, travel inside cells, and work normally. In CDG-IIo, the problem mainly affects the Golgi apparatus (a “packing and finishing” area inside cells), so many organs can be affected, especially the liver and the brain/nervous system. Genetic Diseases Info Center+2PMC+2

Congenital disorder of glycosylation type IIo (often written CDG2O or CDG-IIo) is a very rare genetic disease. It happens when a child is born with changes (mutations) in a gene called CCDC115. This gene helps the Golgi apparatus (a “packing and shipping” part inside cells) add and fix sugar chains on proteins. This sugar-adding process is called glycosylation. When glycosylation is not done correctly, many body systems can be affected at the same time. NCBI+2Orpha+2

In CDG-IIo, reports describe early-life problems such as enlarged liver and spleen, progressive liver disease, low muscle tone (hypotonia), and developmental delay. Some people also have seizures and certain lab changes (for example abnormal liver enzymes and clotting factors). Because it is rare, care is usually supportive and guided by specialists, with treatment focused on the person’s symptoms. Orpha+2NCBI+2

These two names usually mean the same disorder. Many databases list “congenital disorder of glycosylation type 2o” as the same as “congenital disorder of glycosylation type IIo,” and “type IIO” is commonly used as another spelling/format for the same thing. Genetic Diseases Info Center+2disease-ontology.org+2

Other names

This condition may also be called CCDC115-CDG, CDG-IIo, CDG-IIO, CDG2O, or carbohydrate-deficient glycoprotein syndrome type IIo/IIO. Genetic Diseases Info Center+2disease-ontology.org+2

Types

Doctors may describe “types” in two simple ways:

• Old style: CDG type I (early steps in ER) vs CDG type II (processing steps in Golgi/after transfer). PMC+1

• New style (gene-based): the name is based on the gene, so CDG-IIo = CCDC115-CDG. Genetic Diseases Info Center+1

• Glycosylation pathway affected: CCDC115-CDG often shows a combined N-glycosylation and O-glycosylation problem, which fits a Golgi homeostasis defect. PMC+1

Causes

Key idea: The direct cause of CDG-IIo is biallelic (two-copy) disease-causing variants in the gene CCDC115. The extra items below are other genetic causes that can create a CDG type II / Golgi-processing pattern or a similar clinical picture, so they are often considered during diagnosis. Genetic Diseases Info Center+2PMC+2

1. CCDC115 gene variants (the true cause of CDG-IIo): Changes in CCDC115 can disturb Golgi function and lead to abnormal protein glycosylation and the typical liver + neurologic features. PMC+1

2. TMEM199 variants (TMEM199-CDG): TMEM199 is linked to Golgi/V-ATPase related biology; problems can cause glycosylation defects and liver disease that can resemble CCDC115-CDG in some ways. MDPI+1

3. ATP6AP1 variants (ATP6AP1-CDG): A V-ATPase–related disorder that can cause glycosylation abnormalities and multi-system disease, sometimes overlapping with the “Golgi homeostasis” group. LWW Journals+1

4. VMA21 variants (VMA21-CDG): Another V-ATPase assembly factor disorder that can lead to glycosylation problems and significant organ involvement. LWW Journals+1

5. ATP6V0A2 variants (ATP6V0A2-CDG): A Golgi-related glycosylation disorder; some patients have overlapping “type II” transferrin patterns and systemic findings. PMC+1

6. COG7 variants (COG7-CDG): COG complex problems disturb Golgi trafficking and can cause severe CDG type II presentations. NCBI+1

7. COG5 variants (COG5-CDG): Another COG complex disorder that affects Golgi processing of glycans and can show CDG type II patterns. PMC+1

8. COG6 variants (COG6-CDG): A Golgi trafficking disorder; it can cause multi-system disease and abnormal glycosylation tests. PMC+1

9. COG8 variants (COG8-CDG): Another Golgi trafficking gene where defects can lead to CDG type II profiles and neurodevelopmental issues. PMC+1

10. COG4 variants (COG4-CDG): COG4 defects can impair Golgi processing and lead to systemic CDG findings. PMC+1

11. COG1 variants (COG1-CDG): COG1 disruption can produce Golgi glycosylation defects consistent with CDG type II. PMC+1

12. SLC35A1 variants (SLC35A1-CDG): A nucleotide-sugar transporter defect in the Golgi that can cause a CDG type II transferrin pattern. PMC+1

13. SLC35C1 variants (SLC35C1-CDG / LAD-II): A fucose transporter defect causing abnormal glycosylation and immune/other system features. PMC+1

14. B4GALT1 variants (B4GALT1-CDG): A Golgi glycosyltransferase disorder; the phenotype can include neurologic and coagulation issues and abnormal glycosylation testing. Orpha+1

15. MGAT2 variants (MGAT2-CDG / CDG-IIa): A classic Golgi processing enzyme defect producing a type II transferrin pattern and multi-system disease. PMC+1

16. MAN1B1 variants (MAN1B1-CDG): A glycan-processing disorder that can cause neurodevelopmental and systemic features and may show glycosylation abnormalities. PMC+1

17. GCS1 variants (GCS1-CDG / CDG-IIb): A glycosidase defect that affects early trimming steps and can present as a CDG type II disorder. PMC+1

18. GALNT2 variants (GALNT2-CDG): An O-glycosylation–related disorder included in CDG type II lists and considered when glycosylation is abnormal. PMC+1

19. Secondary/combined pathway disruption (Golgi pH and trafficking problems): Some CDGs come from problems that disturb Golgi environment (like pH/trafficking), which can broadly disrupt glycosylation even if the gene is not a “classic” glycosyltransferase. MDPI+1

20. Autosomal recessive inheritance (family genetics): The “cause” in a family is usually inheriting two non-working copies (one from each parent), which is typical for many CDGs including CCDC115-CDG. Genetic Diseases Info Center+1

Symptoms and common clinical signs

Symptoms can vary a lot, but many reported patients have early liver disease plus low muscle tone and developmental delay. Genetic Diseases Info Center+2PMC+2

1. Enlarged liver and spleen (hepatosplenomegaly): Doctors may feel a bigger liver/spleen on exam, often starting in infancy, because the liver is strongly affected. Genetic Diseases Info Center+1

2. Progressive liver failure: The liver may gradually lose function, which can become serious and needs specialist care. Genetic Diseases Info Center+1

3. High liver enzymes (a sign of liver injury): Blood tests may show elevated liver enzymes, reflecting stress or damage in liver cells. Genetic Diseases Info Center+1

4. Low muscle tone (hypotonia): Babies/children may feel “floppy,” have weak head control, or delayed motor milestones. Genetic Diseases Info Center+1

5. Global developmental delay: Development (motor, speech, learning) may be slower than expected across multiple areas. Genetic Diseases Info Center+1

6. Delayed psychomotor development: This means delays in movements and skills that need brain + muscle working together (like sitting, walking, feeding skills). PMC+1

7. Seizures: Some affected children develop seizures, so doctors may watch for staring spells, jerking episodes, or unexplained fainting-like events. Genetic Diseases Info Center+1

8. Feeding difficulties / poor weight gain: Many CDGs can affect growth and feeding, especially when chronic illness and low tone are present. PMC+1

9. Fatigue or low energy: Ongoing liver disease and multi-system stress can make children tire easily and have low stamina. Wiley Online Library+1

10. Bleeding tendency (coagulation problems): Some patients have clotting factor deficiencies, which can cause easy bruising or prolonged bleeding. MalaCards+1

11. High cholesterol (mild hypercholesterolemia): A lipid profile may show high cholesterol, which is reported in this disorder. Genetic Diseases Info Center+1

12. Low ceruloplasmin: This is a blood protein made by the liver; it may be low in CCDC115-CDG and can confuse diagnosis because other liver diseases also affect it. Genetic Diseases Info Center+2metagene.de+2

13. Mild dysmorphic features: Some children have subtle facial/body feature differences that a genetic specialist may notice. Genetic Diseases Info Center+1

14. Elevated alkaline phosphatase (ALP): This lab sign can be high, especially in cholestatic or liver-related disease patterns seen in some patients. PMC+1

15. Muscle weakness or reduced motor endurance: Low tone plus multi-system disease can look like weakness, delayed walking, or limited strength for age. PMC+1

Diagnostic tests

A CDG diagnosis usually uses clinical exam + blood glycosylation tests + genetic testing. Many patients need a team: genetics, hepatology, neurology, and metabolic specialists. PMC+2PMC+2

Physical exam

1. Growth measurements (weight/height/head size): A clinician tracks growth over time to see poor weight gain or slow growth that can happen in multi-system genetic disease. Frontiers+1

2. Abdominal exam for hepatosplenomegaly: The doctor gently feels the belly to check for enlarged liver/spleen, a key clue in CCDC115-CDG. Genetic Diseases Info Center+1

3. Neurologic exam (tone, reflexes, strength): This checks hypotonia, abnormal reflexes, and overall nervous-system function. Genetic Diseases Info Center+1

4. Skin/face and general “dysmorphology” exam: A genetics-focused exam looks for subtle feature patterns that support a syndromic diagnosis. Genetic Diseases Info Center+1

Manual tests (hands-on clinical assessments)

5. Developmental screening (age-based milestone testing): Simple structured tools check speech, movement, and learning skills to document global developmental delay. Genetic Diseases Info Center+1

6. Feeding and swallowing assessment: A clinician or therapist watches feeding to detect poor coordination, fatigue, or aspiration risk in hypotonia and neurologic disease. Frontiers+1

7. Detailed liver disease assessment at bedside: This includes checking for jaundice, itching, swelling, and signs of chronic liver problems that can appear as liver function worsens. PMC+1

8. Family history and pedigree review: Because many CDGs are autosomal recessive, family history (consanguinity, affected siblings) can be a strong clue. Genetic Diseases Info Center+1

Lab and pathological tests

9. Serum transferrin isoelectric focusing (IEF) / CDT testing: This is a classic screening test for many CDGs; type II patterns suggest a processing defect (often Golgi-related). Frontiers+2Frontiers+2

10. Apolipoprotein C-III (ApoC-III) isoform analysis: This helps evaluate O-glycosylation problems and is useful when combined N + O glycosylation defects are suspected. PMC+1

11. Plasma N-glycan / O-glycan profiling by mass spectrometry (“glycomics”): Advanced testing can show detailed glycan changes and support a specific CDG mechanism. Wiley Online Library+1

12. Liver enzymes and liver function panel (AST/ALT, bilirubin, albumin): These show liver injury and how well the liver is working, which is important because progressive liver disease is common. Genetic Diseases Info Center+1

13. Coagulation testing (PT/INR and clotting factors): CDGs can cause clotting factor deficiencies; these tests check bleeding risk and guide safe care. Genetic Diseases Info Center+1

14. Serum ceruloplasmin and lipid profile (cholesterol): Low ceruloplasmin and mild hypercholesterolemia are reported in CCDC115-CDG and help pattern-match the case. Genetic Diseases Info Center+2MalaCards+2

Electrodiagnostic tests

15. EEG (electroencephalogram): If seizures are suspected, EEG looks at brain electrical activity and helps classify seizure types. Genetic Diseases Info Center+1

16. Nerve conduction studies (NCS): If there are concerns about nerve function (weakness, low tone, sensory changes), NCS can check how well nerves conduct signals. PMC+1

17. EMG (electromyography): EMG evaluates muscle electrical activity and helps separate muscle disease from nerve disease when weakness/hypotonia is unclear. PMC+1

Imaging tests

18. Abdominal ultrasound (liver and spleen imaging): Ultrasound can confirm organ enlargement and look for structural liver changes in a safe, non-radiation way. PMC+1

19. Brain MRI: Many CDGs can have brain involvement; MRI helps check for structural changes that may relate to hypotonia, seizures, or delay. PMC+1

20. Liver biopsy (tissue exam) when needed: Sometimes doctors examine a small liver sample to understand fibrosis/steatosis and to rule out other liver diseases; biopsy findings have been described in CCDC115 deficiency. PMC+1

Non-pharmacological treatments (therapies + others)

1. Multidisciplinary care team: Build one main team (metabolic/genetics, liver, neuro, nutrition, rehab). Purpose: catch problems early. Mechanism: regular checks (growth, liver labs, development, feeding) reduce delays in care and prevent crises. PMC+1

2. Genetic counseling for the family: Explain inheritance (often autosomal recessive), recurrence risk, and testing options. Purpose: informed family planning. Mechanism: helps families understand why it happens and supports early diagnosis in future pregnancies/children. NCBI+1

3. Nutrition assessment + high-calorie plan: Many children struggle to grow. Purpose: improve weight and strength. Mechanism: dietitian plans calorie-dense meals, safe textures, and feeding schedules to match energy needs and reduce malnutrition risk. PMC+1

4. Feeding therapy (speech/feeding specialist): If chewing or swallowing is hard. Purpose: safer eating. Mechanism: posture, pacing, texture changes, and swallow exercises reduce choking/aspiration risk and make feeding less exhausting. HSSiEM+1

5. Physical therapy (PT): For hypotonia, delayed milestones, balance issues. Purpose: mobility and independence. Mechanism: strength, stretching, and motor training improve movement patterns and help prevent contractures. PMC+1

6. Occupational therapy (OT): For hand skills, daily activities, sensory issues. Purpose: functional independence. Mechanism: task practice plus adaptive tools helps dressing, writing, feeding, and play. PMC

7. Speech and language therapy: For communication delay. Purpose: better communication. Mechanism: language exercises and AAC (picture boards/devices) reduce frustration and support learning. PMC

8. Development/learning support plan: Early intervention, special education if needed. Purpose: maximize brain development. Mechanism: structured learning and therapies strengthen skills during key growth windows. PMC+1

9. Seizure safety plan (non-drug): Home/school plan for seizure first aid. Purpose: prevent injury. Mechanism: safe environment, supervision during high-risk activities, and clear emergency steps. Genetic Diseases Info Center+1

10. Liver-focused monitoring: Regular liver enzymes, bilirubin, albumin, ultrasound as advised. Purpose: detect worsening early. Mechanism: tracking trends helps doctors act early for nutrition, bleeding risk, or transplant evaluation. Orpha+1

11. Bleeding-risk planning: If clotting factors are low, plan procedures carefully. Purpose: prevent dangerous bleeding. Mechanism: labs before surgery/dental work and hospital protocols reduce complications. NCBI+1

12. Vaccination optimization: Keep routine vaccines updated; consider extra protection if advised. Purpose: infection prevention. Mechanism: fewer infections means fewer metabolic “stress events” and fewer hospitalizations. PMC+1

13. Hand hygiene + infection control at home: Simple rules for family/school. Purpose: reduce infections. Mechanism: fewer viruses/bacteria entering the body lowers fever episodes and stress on liver/brain. PMC

14. Respiratory support when needed: Chest physiotherapy, suction training, sleep assessment. Purpose: protect lungs. Mechanism: improves airway clearance and reduces pneumonia risk, especially if swallowing is weak. HSSiEM+1

15. Regular hearing and vision checks: Some rare disorders affect these areas. Purpose: support learning. Mechanism: glasses/hearing aids early reduce language and school delays. PMC

16. Safe activity program: Gentle daily movement, avoid over-fatigue. Purpose: build stamina safely. Mechanism: consistent low-risk exercise supports muscle and bone health without triggering exhaustion. PMC

17. Sleep routine + behavior supports: Fixed sleep times, calming routine. Purpose: better energy and attention. Mechanism: good sleep reduces seizure triggers and improves learning readiness. PMC

18. Psychological support for family: Counseling, caregiver support groups. Purpose: reduce stress and burnout. Mechanism: emotional support improves long-term care quality and family stability. PMC

19. Emergency letter (“rare disease passport”): One page with diagnosis, risks, key labs, and contacts. Purpose: safer ER care. Mechanism: speeds correct decisions during fever, seizures, vomiting, or bleeding concerns. PMC+1

20. Regular reassessment of goals: Every 6–12 months, update plans. Purpose: keep care realistic and effective. Mechanism: needs change over time; periodic review prevents outdated therapy and missed problems. PMC

Drug treatments

These medicines do not “fix” the gene problem. They are commonly used to treat complications (seizures, reflux, infections, hormone issues, bleeding risk, etc.). Doses below are typical label patterns; the correct dose depends on age, weight, liver function, and doctor judgment. PMC+1

1. Levetiracetam (KEPPRA) — Class: antiepileptic. Dose/Time: often twice daily; titrated. Purpose: seizure control. Mechanism: helps stabilize brain signaling and reduces seizure frequency. Side effects: sleepiness, dizziness, mood/behavior changes in some people. FDA Access Data

2. Topiramate (TOPAMAX) — Class: antiepileptic. Dose/Time: slow titration over weeks. Purpose: seizures (and sometimes migraine prevention). Mechanism: reduces over-excitation in the brain through multiple pathways. Side effects: tingling, appetite/weight loss, thinking “slow,” kidney stones, metabolic acidosis risk. FDA Access Data

3. Clobazam (ONFI) — Class: benzodiazepine antiepileptic. Dose/Time: daily dosing, adjusted gradually. Purpose: seizure reduction (often as add-on). Mechanism: boosts GABA calming signals in the brain. Side effects: sleepiness, drooling, behavior changes, dependence/withdrawal if stopped suddenly. FDA Access Data

4. Phenobarbital — Class: barbiturate antiepileptic. Dose/Time: individualized dosing; sometimes used long-term or in emergencies. Purpose: seizure control. Mechanism: strengthens inhibitory (GABA) activity to calm the brain. Side effects: sedation, learning/attention slowing, rash, dependence; overdose risk if misused. FDA Access Data+1

5. Ethosuximide (Zarontin) — Class: anticonvulsant succinimide. Dose/Time: daily dosing, adjusted. Purpose: absence seizures (if present). Mechanism: reduces certain calcium currents involved in absence seizures. Side effects: stomach upset, fatigue, headache; rare blood or liver problems. FDA Access Data

6. Baclofen — Class: antispasticity (GABA-B agonist). Dose/Time: usually multiple daily doses; taper to stop. Purpose: stiffness/spasticity (if present). Mechanism: relaxes overactive muscle signals in the spinal cord. Side effects: sleepiness, weakness, dizziness; sudden stopping can be dangerous. FDA Access Data

7. Omeprazole (PRILOSEC) — Class: proton pump inhibitor. Dose/Time: often once daily for weeks, sometimes longer. Purpose: reflux/heartburn, stomach irritation. Mechanism: lowers stomach acid production. Side effects: headache, diarrhea; long use can affect minerals/infection risk in some people. FDA Access Data

8. Ondansetron (ZOFRAN) — Class: anti-nausea (5-HT3 blocker). Dose/Time: given before/after nausea triggers as directed. Purpose: vomiting control. Mechanism: blocks serotonin signals that trigger nausea/vomiting. Side effects: constipation, headache; heart rhythm risk in susceptible people. FDA Access Data

9. Ursodiol (URSO 250 / URSO Forte) — Class: bile acid. Dose/Time: weight-based daily dosing with food. Purpose: certain cholestatic liver problems. Mechanism: improves bile flow and reduces bile toxicity in liver/bile ducts. Side effects: diarrhea, abdominal discomfort in some. FDA Access Data

10. Amoxicillin (AMOXIL) — Class: penicillin antibiotic. Dose/Time: usually 2–3 times daily for a set number of days. Purpose: treat susceptible bacterial infections. Mechanism: blocks bacterial cell wall building. Side effects: diarrhea, rash; allergy reactions can occur. FDA Access Data

11. Ceftriaxone (for Injection) — Class: cephalosporin antibiotic. Dose/Time: IV/IM dosing in hospital/clinic, often once daily. Purpose: more serious infections. Mechanism: blocks bacterial cell wall synthesis. Side effects: diarrhea, injection-site pain; gallbladder “sludge” can occur in some patients. FDA Access Data

12. Levothyroxine — Class: thyroid hormone. Dose/Time: once daily; dose is lab-guided. Purpose: treat hypothyroidism if present. Mechanism: replaces missing thyroid hormone to support metabolism, growth, and brain function. Side effects: too high a dose can cause fast heart rate, anxiety, weight loss. FDA Access Data

13. Hydrocortisone (oral) — Class: glucocorticoid steroid. Dose/Time: daily split dosing; “stress dosing” during illness if prescribed. Purpose: adrenal insufficiency (if present). Mechanism: replaces cortisol needed for blood pressure, glucose control, and stress response. Side effects: weight gain, mood changes, infection risk at high doses. FDA Access Data

14. Phytonadione (Vitamin K1) injection — Class: vitamin/coagulation support. Dose/Time: given as directed for deficiency/bleeding risk. Purpose: help clotting when vitamin K–dependent factors are low. Mechanism: supports production of clotting proteins in the liver. Side effects: injection reactions; dosing must be supervised. FDA Access Data

15. Midodrine (PROAMATINE) — Class: alpha-1 agonist. Dose/Time: typically daytime dosing (multiple doses); avoid near bedtime if advised. Purpose: symptomatic low blood pressure (if present). Mechanism: tightens blood vessels to raise blood pressure. Side effects: high BP lying down, tingling scalp, goosebumps. FDA Access Data

16. Spironolactone (ALDACTONE) — Class: potassium-sparing diuretic/aldosterone antagonist. Dose/Time: daily dosing, adjusted with labs. Purpose: fluid retention/ascites in some liver conditions. Mechanism: reduces sodium/water retention driven by aldosterone. Side effects: high potassium, breast tenderness; needs monitoring. FDA Access Data

17. Droxidopa (NORTHERA) — Class: prodrug of norepinephrine. Dose/Time: three times daily with titration. Purpose: neurogenic orthostatic hypotension (selected cases). Mechanism: increases norepinephrine to raise standing BP. Side effects: headache, dizziness, nausea, hypertension. FDA Access Data

18. Filgrastim (NEUPOGEN) — Class: G-CSF growth factor. Dose/Time: injections as prescribed. Purpose: severe neutropenia/recurrent infections in selected cases. Mechanism: stimulates bone marrow to make more neutrophils. Side effects: bone pain, spleen enlargement risk; needs specialist care. FDA Access Data

19. Plerixafor (MOZOBIL) — Class: stem-cell mobilizer (CXCR4 antagonist). Dose/Time: injections in specialized settings. Purpose: mobilize stem cells for collection (not a routine CDG therapy). Mechanism: moves stem cells from marrow into blood for collection. Side effects: diarrhea, injection reactions, dizziness. FDA Access Data

20. Somatropin (growth hormone products) — Class: anabolic hormone. Dose/Time: injections, dose based on weight and response. Purpose: short stature/growth failure in selected diagnoses; not specific to CDG-IIo. Mechanism: increases IGF-1 and supports growth and protein building. Side effects: swelling, joint pain; needs endocrinology monitoring. FDA Access Data

Dietary molecular supplements

Supplements can help deficiencies and nutrition, but they do not “cure” CDG-IIo. Use them only with a clinician, especially if there is liver disease or bleeding risk. PMC+1

1. Vitamin D3 — Dose: commonly 600–1000 IU/day (or as lab-guided). Function: bone and immune support. Mechanism: helps calcium absorption and bone mineralization; may support immune signaling. HSSiEM+1

2. Calcium — Dose: age-based dietary goal; supplement only if intake is low. Function: bones, muscle contraction. Mechanism: builds bone matrix and supports nerve/muscle signaling. HSSiEM+1

3. Iron (if deficient) — Dose: clinician-set based on ferritin/Hb. Function: prevent/treat anemia. Mechanism: supports hemoglobin and oxygen delivery to tissues. PMC+1

4. Zinc — Dose: small daily dose if intake is low. Function: growth, immunity, wound healing. Mechanism: supports enzyme function and immune cell activity. PMC

5. Magnesium — Dose: modest daily dose if needed. Function: muscle/nerve function. Mechanism: stabilizes energy reactions and nerve signaling; may help cramps in some people. PMC

6. Omega-3 (EPA/DHA) — Dose: low-to-moderate daily intake. Function: brain and heart support. Mechanism: supports cell membranes and reduces inflammatory signaling in some contexts. PMC+1

7. Coenzyme Q10 (CoQ10) — Dose: clinician-guided (often split doses). Function: energy support. Mechanism: part of mitochondrial electron transport; sometimes tried in complex metabolic conditions though evidence varies. ScienceDirect+1

8. L-carnitine — Dose: only if low or if doctor recommends. Function: energy/fat metabolism support. Mechanism: helps transport fatty acids into mitochondria; used in some metabolic disorders when indicated. ScienceDirect+1

9. B-complex (especially B12/folate if low) — Dose: near RDA unless deficiency is confirmed. Function: nerve and blood cell support. Mechanism: supports DNA and red blood cell production and nerve function. PMC

10. Oral rehydration salts (ORS) during diarrhea/vomiting — Dose: small frequent sips. Function: prevent dehydration. Mechanism: glucose-salt transport improves water absorption in the gut. HSSiEM+1

Immunity booster / regenerative / stem-cell” drug options

In CDG, advanced therapies are usually case-by-case and aimed at complications, not the root gene defect. Always require a specialist. ScienceDirect+1

1. Filgrastim (G-CSF) — Dose: injection schedules vary. Function: raises neutrophils when severely low. Mechanism: stimulates marrow neutrophil production; may reduce infection frequency in selected patients. FDA Access Data

2. Plerixafor — Dose: injection in controlled setting. Function: mobilize stem cells for collection. Mechanism: blocks CXCR4 so stem cells move into blood; used for transplant procedures, not routine CDG care. FDA Access Data

3. Somatropin (growth hormone) — Dose: weight-based injections. Function: supports growth/anabolism in selected endocrine situations. Mechanism: increases IGF-1 and protein building; can improve growth parameters when appropriate. FDA Access Data

4. Hydrocortisone (stress-dose protocol when prescribed) — Dose: temporary higher dosing during illness for adrenal insufficiency. Function: supports immune-stress response safely. Mechanism: replaces cortisol so the body can handle fever/infection stress without shock. FDA Access Data

5. Vitamin K (phytonadione) when clotting is weak — Dose: clinician-directed. Function: supports recovery during bleeding risk states. Mechanism: helps liver make clotting proteins; indirectly supports safer healing. FDA Access Data

6. Ceftriaxone (serious infections) — Dose: hospital dosing. Function: infection control when needed. Mechanism: treats susceptible bacteria quickly, lowering body stress that can worsen metabolic illness. FDA Access Data

 Surgeries / procedures

1. Gastrostomy tube (G-tube) placement — Why: poor intake, unsafe swallow, failure to thrive. What it does: gives nutrition directly to stomach to support growth and reduce aspiration risk. HSSiEM+1

2. Anti-reflux surgery (fundoplication) in selected cases — Why: severe reflux with aspiration or poor growth despite treatment. What it does: strengthens the valve between esophagus and stomach to reduce reflux. HSSiEM+1

3. Central venous access device (port/central line) — Why: frequent blood tests, IV antibiotics, or supportive infusions. What it does: safer repeated IV access, but requires infection-prevention care. PMC

4. Liver transplant evaluation and transplant (rare, severe liver failure) — Why: progressive liver failure not manageable with supportive care. What it does: replaces failing liver; requires lifelong specialist follow-up. Orpha+1

5. Orthopedic procedures (contracture release / hip surgery) when needed — Why: tight muscles, joint problems affecting walking/sitting. What it does: improves position, comfort, and mobility when therapy alone is not enough. PMC

Prevention tips

1. Keep all routine vaccines updated (and follow specialist advice). HSSiEM+1

2. Handwashing and infection-avoidance routines at home/school. PMC

3. Early treatment of fever and dehydration (do not “wait it out”). PMC+1

4. Regular liver monitoring appointments. NCBI+1

5. Plan procedures early if clotting is abnormal (dentist/surgery). NCBI+1

6. Safe feeding strategies to prevent choking/aspiration. HSSiEM+1

7. Keep seizure triggers low: good sleep, hydration, medication routine. PMC+1

8. Avoid unprescribed supplements/meds that stress the liver. PMC+1

9. Use a medical alert card and an emergency plan. PMC+1

10. Regular growth/development screening so therapy starts early. PMC+1

When to see a doctor (urgent warning signs)

Go to urgent care/ER now for: repeated seizures, trouble breathing, blue lips, severe sleepiness, fainting, uncontrolled vomiting, signs of dehydration (very little urine, dry mouth), black/bloody stool, vomiting blood, or new/worsening jaundice (yellow eyes/skin). Orpha+2NCBI+2

Call the doctor soon for: poor feeding, weight loss, persistent diarrhea, frequent infections, easy bruising/bleeding, new swelling of belly/legs, or developmental regression (losing skills). NCBI+1

What to eat and what to avoid

1. Eat: calorie-dense meals/snacks. Avoid: long fasting.

2. Eat: enough protein (eggs, fish, dairy if tolerated, legumes). Avoid: very low-protein diets unless prescribed.

3. Eat: fruits/vegetables for vitamins. Avoid: ultra-processed foods as the main diet.

4. Eat: safe textures (puree/soft) if swallowing is weak. Avoid: hard/dry foods that increase choking risk.

5. Eat: healthy fats (olive oil, nuts/seed butter if safe). Avoid: trans-fats.

6. Eat: ORS/fluids during illness. Avoid: dehydration.

7. Eat: smaller frequent meals if nausea/reflux. Avoid: large late meals if reflux is bad.

8. Eat: low-salt plan only if doctor says. Avoid: sudden salt changes without medical advice (important in BP/liver care).

9. Eat: food-based vitamins first. Avoid: high-dose supplements without labs (especially with liver disease).

10. Eat: culturally normal balanced diet that the child accepts. Avoid: forcing unsafe feeding; use feeding therapy instead.

FAQs

1. Is CDG-IIo curable? No single cure is known. Care focuses on symptoms and preventing complications.

2. Is CDG-IIo the same as “CCDC115-CDG”? Yes, CDG-IIo (CDG2O) is linked to CCDC115 gene changes.

3. How is it inherited? Most reports describe autosomal recessive inheritance (both parents are carriers).

4. What body parts are commonly affected? Liver function, muscle tone, growth, and development are often involved; seizures can occur.

5. Why does the liver get affected? Faulty glycosylation can disrupt how liver proteins work and how cells handle stress.

6. Can diet alone treat CDG-IIo? Diet cannot fix the gene defect, but good nutrition can improve strength and growth.

7. Are seizures common? They have been reported in some patients, so monitoring is important.

8. Which seizure medicine is “best”? There is no single best. Doctors choose based on seizure type, age, and side-effect risk.

9. Can liver transplant be needed? In severe progressive liver failure, transplant evaluation may be considered.

10. Does every patient need a feeding tube? No. It is considered when oral feeding is unsafe or growth is failing.

11. Are antibiotics used long-term? Only if infections require them; unnecessary use can cause side effects and resistance.

12. Should families do genetic testing? Often yes, for confirmation, family planning, and sometimes for research or trials.

13. Are supplements always safe? Not always—high doses can be risky, especially with liver disease. Use labs and clinician guidance.

14. What specialists are usually needed? Genetics/metabolic, hepatology, neurology, nutrition, and therapy services are common.

15. What research exists for CDG treatments? Reviews show growing research, but for many CDG types, treatment remains mostly supportive today.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 15, 2025.